Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Oct-Dec;65(4):775-780.
doi: 10.47162/RJME.65.4.24.

Biology of recurrent cholesteatoma in a Romanian young patient - a case report

Ramona Andreea Bologa  1 , Florin Anghelina, Mihaela Roxana Mitroi, Mircea Sorin Ciolofan, Carmen Aurelia Mogoantă, Alina Nicoleta Căpitănescu, Alexandru Florian Grecu, Liliana Anghelina, Mihai Marius Botezat, Alina Andreea Mogoş, Bogdan Marius Fănuţă, Ileana Marinescu, Dan Cristian Grecu
Affiliations
Case Reports

Biology of recurrent cholesteatoma in a Romanian young patient - a case report

Ramona Andreea Bologa et al. Rom J Morphol Embryol. 2024 Oct-Dec.

Abstract

Cholesteatoma is an otologic pathology that can occur at any age and can lead to a variety of complications including facial palsy, intracranial abscess, hearing loss, venous thrombosis. Cholesteatoma, even if considered a benign condition, associates high risks of recurrency due to its invasiveness. We describe a case of recurrent cholesteatoma in a young boy who presented chronic ear discharge and hearing loss for which had undergone three surgical interventions between the ages of 16 and 19 years old, from 2019 to 2022. Pediatric cholesteatoma is more prone to recurrency. Considering surgical excision as the only treatment at the current moment, it is highly important to understand the biology of cholesteatoma lesional extension for further treatment management improvement. Good research of angiogenesis, chronic inflammation and immune infiltration correlated with surgical approach may be the future for preventing cholesteatoma recurrency.

Keywords: CD20; CD3; CD34; CD68; CD79α; recurrent cholesteatoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interests.

Figures

Figure 1
Figure 1
Axial computed tomography (CT) scan for the left temporal bone showed opacification of the surgical cavity, bone condensation in the left mastoid cavity and destruction of the external wall
Figure 2
Figure 2
Axial CT scan for the left temporal bone showed opacification of the surgical cavity, bone condensation in the left mastoid cavity and destruction of the external wall with partial erosion of the ossicles
Figure 3
Figure 3
Cholesteatoma sample: neoformation for vascular patterns and inflammatory infiltrate in the matrix. Hematoxylin–Eosin (HE) staining, ×200
Figure 4
Figure 4
Cholesteatoma sample: perimatrix shows vessel proliferation and angiogenesis in the stroma with CD34-positive endothelial cells. Anti-CD34 antibody immunomarking, ×200. CD34: Cluster of differentiation 34
Figure 5
Figure 5
Cholesteatoma sample: high perivascular abundance of mast cells (brownish) and angiogenesis, immunoreactive for tryptase. Anti-tryptase antibody immunomarking, ×100
Figure 6
Figure 6
Cholesteatoma sample: stroma with numerous uninuclear macrophages, immunoreactive for CD68. Anti-CD68 antibody immunomarking, ×200. CD68: Cluster of differentiation 68
Figure 7
Figure 7
Cholesteatoma sample: stroma with perivascular inflammatory infiltrate abundance of B-lymphocytes and plasma cells, immunoreactive for CD79α. Anti-CD79α antibody immunomarking, ×200. CD79α: Cluster of differentiation 79 alpha
Figure 8
Figure 8
Cholesteatoma sample: stroma with perivascular inflammatory infiltrate of B-lymphocytes, immunoreactive for CD20. Anti-CD20 antibody immunomarking, ×200. CD20: Cluster of differentiation 20
Figure 9
Figure 9
Cholesteatoma sample: stroma with perivascular inflammatory infiltrate abundant in T-lymphocytes, immunoreactive for CD3. Anti-CD3 antibody immunomarking, ×200. CD3: Cluster of differentiation 3.
See this image and copyright information in PMC

References

    1. Yung M, Tono T, Olszewska E, Yamamoto Y, Sudhoff H, Sakagami M, Mulder J, Kojima H, İncesulu A, Trabalzini F, Özgirgin N. EAONO/JOS Joint Consensus Statements on the definitions, classification and staging of middle ear cholesteatoma. J Int Adv Otol. 2017;13(1):1–8. - PubMed
    1. Maniu A, Harabagiu O, Perde Schrepler, Cătană A, Fănuţă B, Mogoantă CA. Molecular biology of cholesteatoma. Rom J Morphol Embryol. 2014;55(1):7–13. - PubMed
    1. Cantone E, Di Nola, De Corso, Cavaliere M, Grimaldi G, Fetoni AR, Motta G. Endotyping of cholesteatoma: which molecular biomarkers? A systematic review. J Pers Med. 2022;12(8):1347–1347. - PMC - PubMed
    1. Louw L. Acquired cholesteatoma: summary of the cascade of molecular events. J Laryngol Otol. 2013;127(6):542–549. - PubMed
    1. Hussein MRA, Sayed RH, Abu-Dief EE. Immune cell profile in invasive cholesteatomas: preliminary findings. Exp Mol Pathol. 2010;88(2):316–323. - PubMed

Publication types

LinkOut - more resources